Oncology Drug Reference Sheet: Talazoparib
Kristine B. LeFebvre DNP, RN, NPD-BC, AOCN®
Voice
Description
Initially approved in 2018, talazoparib (Talzenna®) capsules are indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene HER2-negative locally advanced or metastatic breast cancer.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education